BSE · 539561
Supha Pharmachem Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹9 Cr with net profit ₹0 Cr — a 0.82% net margin, versus -2.01% the period before.
Shareholding
As of 2025-12-31
- Promoter1.13%
- Public97.17%
- FII1.7%
1,11,269 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 7.2× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — IBC. Trading may carry price bands, periodic call auction or higher margins.
- 52-week range spans 7.2× (₹0.25 to ₹1.8) — an unusually wide band.
Peer comparison
Trading · ranked #317 of 666 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,93,459 Cr | 24.35 | 4.83 | 3.42% | 9.3% |
| Avenue Supermarts Limited | ₹2,50,959 Cr | 381.38 | 10.26 | 12.14% | 4.32% |
| Trent Ltd. | ₹1,60,247 Cr | 266.89 | 22.94 | 24.62% | 8.57% |
| FSN E-Commerce Ventures Ltd. | ₹93,790 Cr | 1212.96 | 65.21 | 13.87% | 1.99% |
| Vishal Mega Mart Limited | ₹50,703 Cr | 300.67 | 6.82 | 11.32% | 6.61% |
| Premier Energies Limited | ₹47,038 Cr | 102.19 | 10.91 | 35.05% | 19.3% |
| Aegis Logistics Limited | ₹45,019 Cr | 109.72 | 7.44 | 14.83% | 10.78% |
| Aditya Infotech Limited | ₹40,364 Cr | 238.34 | 21.5 | 19.61% | 8.72% |
| Redington Limited | ₹22,472 Cr | 57.38 | 2.21 | 14.67% | 1.25% |
| Honasa Consumer Limited | ₹14,620 Cr | 210.96 | 10.36 | 14.16% | 8.36% |
| Supha Pharmachem Limited(this company) | ₹29 Cr | 16.5 | 0.32 | 0% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashSupha Pharmachem Limited, with a market capitalization of Rs 28 Cr, reported revenue of Rs 416.05 Cr. The company's PE ratio stands at 16, and its book value is Rs 1.04. The EPS is Rs 0.02.
Positives
- +No promoter shares are pledged, with promoter pledge at 0%.
Negatives
- −The company's debt-to-equity ratio is high at 26.01.
- −Promoter holding is very low at 1.1276% as of December 31, 2025.
- −The Return on Equity (ROE) is 0%, indicating no return generation for shareholders.
- −The Return on Capital Employed (ROCE) is 0%, suggesting inefficient use of capital.
- −Supha Pharmachem Limited is currently under IBC surveillance.
Financial performance
The company reported an annual revenue of Rs 416.05 Cr for the period ending March 2025. Net profit for the same period was Rs 2.1294 Cr. Quarterly revenue for March 2025 was Rs 264.32 Cr, with a net profit of -Rs 2.05 Cr. For the period ending September 2025, revenue was Rs 8.58 Cr and net profit was Rs 0.07 Cr. For the period ending June 2025, revenue was Rs 18.37 Cr and net profit was -Rs 0.37 Cr.
Profitability & returns
Supha Pharmachem Limited recorded an EPS of Rs 0.02. The company's profit margin was 0%, with Nil Return on Equity (ROE) and Nil Return on Capital Employed (ROCE). EBITDA for the year ending March 2025 was Rs 9.673 Cr.
Balance sheet
The debt-to-equity ratio of the company is 26.01, indicating a high reliance on debt. The book value per share is Rs 1.04. From the provided data, the company's dividend yield is 0%.
Ownership & pledges
Public shareholding stands at 97.1717%. There are no recorded promoter pledges.
Regulatory & surveillance
Supha Pharmachem Limited is currently under surveillance by the IBC (Insolvency and Bankruptcy Code).
Data as of — price: 2026-07-30 · financials: Sep 25 · shareholding: Dec 25. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.